{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:18:55Z","timestamp":1791314335910,"version":"4.3.1"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1038\/ncponc0688","type":"journal-article","created":{"date-parts":[[2006,12,21]],"date-time":"2006-12-21T10:48:08Z","timestamp":1166698088000},"page":"42-55","source":"Crossref","is-referenced-by-count":104,"title":["Therapy Insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease"],"prefix":"10.1038","volume":"4","author":[{"given":"Colin R","family":"Dunstan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Felsenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus J","family":"Seibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncponc0688_CR1","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman UA et al. (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333: 1437\u20131443","journal-title":"N Engl J Med"},{"key":"BFncponc0688_CR2","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM et al. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348: 1535\u20131541","journal-title":"Lancet"},{"key":"BFncponc0688_CR3","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR et al. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280: 2077\u20132082","journal-title":"JAMA"},{"key":"BFncponc0688_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/PL00004171","volume":"9","author":"HA Pols","year":"1999","unstructured":"Pols HA et al. (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 9: 461\u2013468","journal-title":"Osteoporos Int"},{"key":"BFncponc0688_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11: 83\u201391","journal-title":"Osteoporos Int"},{"key":"BFncponc0688_CR6","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282: 1344\u20131352","journal-title":"JAMA"},{"key":"BFncponc0688_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1185\/030079903125003125","volume":"20","author":"C Roux","year":"2004","unstructured":"Roux C et al. (2004) Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20: 433\u2013439","journal-title":"Curr Med Res Opin"},{"key":"BFncponc0688_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.bone.2005.05.004","volume":"37","author":"D Felsenberg","year":"2005","unstructured":"Felsenberg D et al. (2005) Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 37: 651\u2013654","journal-title":"Bone"},{"key":"BFncponc0688_CR9","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1359\/JBMR.050313","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD et al. (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20: 1315\u20131322","journal-title":"J Bone Miner Res"},{"key":"BFncponc0688_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344: 333\u2013340","journal-title":"N Engl J Med"},{"key":"BFncponc0688_CR11","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJMoa044241","volume":"353","author":"IR Reid","year":"2005","unstructured":"Reid IR et al. (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 353: 898\u2013908","journal-title":"N Engl J Med"},{"key":"BFncponc0688_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/bmj.327.7413.469","volume":"327","author":"JR Ross","year":"2003","unstructured":"Ross JR et al. (2003) Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 327: 469\u2013472","journal-title":"BMJ"},{"key":"BFncponc0688_CR13","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1023\/A:1012506426440","volume":"12","author":"SP Jagdev","year":"2001","unstructured":"Jagdev SP et al. (2001) Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 12: 1433\u20131438","journal-title":"Ann Oncol"},{"key":"BFncponc0688_CR14","first-page":"478","volume":"7","author":"JR Berenson","year":"2001","unstructured":"Berenson JR et al. (2001) A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 7: 478\u2013485","journal-title":"Clin Cancer Res"},{"key":"BFncponc0688_CR15","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJM199810013391402","volume":"339","author":"FH Glorieux","year":"1998","unstructured":"Glorieux FH et al. (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339: 947\u2013952","journal-title":"N Engl J Med"},{"key":"BFncponc0688_CR16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1136\/adc.86.5.356","volume":"86","author":"E Astrom","year":"2002","unstructured":"Astrom E and Soderhall S (2002) Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 86: 356\u2013364","journal-title":"Arch Dis Child"},{"key":"BFncponc0688_CR17","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1126\/science.165.3899.1262","volume":"165","author":"H Fleisch","year":"1969","unstructured":"Fleisch H et al. (1969) Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165: 1262\u20131264","journal-title":"Science"},{"issue":"Suppl 12","key":"BFncponc0688_CR18","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","volume":"88","author":"MJ Rogers","year":"2000","unstructured":"Rogers MJ et al. (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 (Suppl 12): 2961\u20132978","journal-title":"Cancer"},{"key":"BFncponc0688_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"JH Lin","year":"1996","unstructured":"Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18: 75\u201385","journal-title":"Bone"},{"key":"BFncponc0688_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/BF02196199","volume":"6","author":"RG Russell","year":"1970","unstructured":"Russell RG et al. (1970) The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res 6: 183\u2013196","journal-title":"Calcif Tissue Res"},{"key":"BFncponc0688_CR21","first-page":"326","volume":"11","author":"R Schenk","year":"1973","unstructured":"Schenk R et al. (1973) Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Int 11: 326\u2013331","journal-title":"Calcif Tissue Int"},{"key":"BFncponc0688_CR22","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1124\/mol.105.020776","volume":"69","author":"K Thompson","year":"2006","unstructured":"Thompson K et al. (2006) Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 69: 1624\u20131632","journal-title":"Mol Pharmacol"},{"key":"BFncponc0688_CR23","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1172\/JCI115539","volume":"88","author":"M Sato","year":"1991","unstructured":"Sato M et al. (1991) Bisphosphonate action: alendronate localization in rat bone osteoclast ultrastructure. J Clin Invest 88: 2095\u20132105","journal-title":"J Clin Invest"},{"key":"BFncponc0688_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/BF00318625","volume":"260","author":"N Van Rooijen","year":"1990","unstructured":"Van Rooijen N et al. (1990) Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate. Cell Tissue Res 260: 215\u2013222","journal-title":"Cell Tissue Res"},{"key":"BFncponc0688_CR25","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.2174\/1381612033453640","volume":"9","author":"MJ Rogers","year":"2003","unstructured":"Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9: 2643\u20132658","journal-title":"Curr Pharm Des"},{"key":"BFncponc0688_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1445-5994.1983.tb04658.x","volume":"13","author":"RA Evans","year":"1983","unstructured":"Evans RA et al. (1983) Pathologic fracture due to severe osteomalacia following diphosphonate treatment of Paget's disease of bone. Aust NZ J Med 13: 277\u2013279","journal-title":"Aust NZ J Med"},{"key":"BFncponc0688_CR27","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(84)92272-4","volume":"1","author":"BF Boyce","year":"1984","unstructured":"Boyce BF et al. (1984) Focal osteomalacia due to low-dose diphosphonate therapy in disease. Lancet 1: 821\u2013824","journal-title":"Lancet"},{"key":"BFncponc0688_CR28","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0140-6736(94)92446-5","volume":"343","author":"BF Boyce","year":"1994","unstructured":"Boyce BF et al. (1994) Mineralisation defects after pamidronate for Paget's. Lancet 343: 1231\u20131232","journal-title":"Lancet"},{"key":"BFncponc0688_CR29","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1210\/jcem-55-6-1100","volume":"55","author":"S Harris","year":"1982","unstructured":"Harris S et al. (1982) Secondary hyperparathyroidism associated with dichloromethane diphosphonate treatment of Paget's disease. J Clin Endocrinol Metab 55: 1100\u20131107","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncponc0688_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0885-3924(02)00644-9","volume":"25","author":"C Champallou","year":"2003","unstructured":"Champallou C et al. (2003) Hypocalcemia following pamidronate administration for bone solid tumor: three clinical case reports. J Pain Symptom Manage 25: 185\u2013190","journal-title":"J Pain Symptom Manage"},{"key":"BFncponc0688_CR31","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1046\/j.1365-2141.2002.03835_4.x","volume":"119","author":"SG Jones","year":"2002","unstructured":"Jones SG et al. (2002) Severe increase in creatinine with hypocalcaemia in myeloma patients receiving zoledronic acid infusions. Br J Haematol 119: 576\u2013577","journal-title":"Br J Haematol"},{"key":"BFncponc0688_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/082585979601200109","volume":"12","author":"E McIntyre","year":"1996","unstructured":"McIntyre E and Bruera E (1996) Symptomatic hypocalcemia after intravenous pamidronate. J Palliative Care 12: 46\u201347","journal-title":"J Palliative Care"},{"key":"BFncponc0688_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1385\/ENDO:14:2:159","volume":"14","author":"A Mishra","year":"2001","unstructured":"Mishra A et al. (2001) Prolonged, symptomatic hypocalcemia with pamidronate subclinical hypoparathyroidism. Endocrine 14: 159\u2013164","journal-title":"Endocrine"},{"key":"BFncponc0688_CR34","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/S0140-6736(05)79826-3","volume":"352","author":"CS Haworth","year":"1998","unstructured":"Haworth CS et al. (1998) Severe bone pain after intravenous pamidronate in adult cystic fibrosis. Lancet 352: 1753\u20131754","journal-title":"Lancet"},{"key":"BFncponc0688_CR35","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1590\/S1516-31801998000500002","volume":"116","author":"M Duarte","year":"1998","unstructured":"Duarte M et al. (1998) The spectrum of bone disease in 200 chronic hemodialysis patients: a correlation between clinical, biochemical and histological findings. Sao Paulo Med J 116: 1790\u20131797","journal-title":"Sao Paulo Med J"},{"key":"BFncponc0688_CR36","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S8756-3282(01)00414-8","volume":"28","author":"T Mashiba","year":"2001","unstructured":"Mashiba T et al. (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28: 524\u2013531","journal-title":"Bone"},{"key":"BFncponc0688_CR37","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"H Bone","year":"2004","unstructured":"Bone H et al. (2004) Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189\u20131199","journal-title":"N Engl J Med"},{"key":"BFncponc0688_CR38","first-page":"3787","volume":"12","author":"A Parfitt","year":"2003","unstructured":"Parfitt A (2003) Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Op Nephrol Hypertension 12: 3787\u20133403","journal-title":"Curr Op Nephrol Hypertension"},{"key":"BFncponc0688_CR39","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2001","unstructured":"Odvina CV et al. (2001) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90: 1294\u20131301","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncponc0688_CR40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","volume":"139","author":"RE Hewitt","year":"2005","unstructured":"Hewitt RE et al. (2005) The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139: 101\u2013111","journal-title":"Clin Exp Immunol"},{"key":"BFncponc0688_CR41","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1359\/JBMR.0301230","volume":"19","author":"K Thompson","year":"2004","unstructured":"Thompson K and Rogers MJ (2004) Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro. J Bone Miner Res 19: 278\u2013288","journal-title":"J Bone Miner Res"},{"key":"BFncponc0688_CR42","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/BF02556671","volume":"41","author":"S Adami","year":"1987","unstructured":"Adami S et al. (1987) The acute-phase response after bisphosphonate. Calcif Tissue Int 41: 326\u2013331","journal-title":"Calcif Tissue Int"},{"key":"BFncponc0688_CR43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1124\/mol.59.2.193","volume":"59","author":"AA Reszka","year":"2001","unstructured":"Reszka AA et al. (2001) Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 59: 193\u2013202","journal-title":"Mol Pharmacol"},{"key":"BFncponc0688_CR44","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1023\/A:1005574009856","volume":"45","author":"L Lichtenberger","year":"2000","unstructured":"Lichtenberger L et al. (2000) Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci 45: 1792\u20131801","journal-title":"Dig Dis Sci"},{"key":"BFncponc0688_CR45","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","volume":"335","author":"PC de Groen","year":"1996","unstructured":"de Groen PC et al. (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335: 1016\u20131021","journal-title":"N Engl J Med"},{"key":"BFncponc0688_CR46","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s100670050116","volume":"18","author":"N Demerjian","year":"1999","unstructured":"Demerjian N et al. (1999) Severe oral ulcerations induced by alendronate. Clin Rheumatol 18: 349\u2013350","journal-title":"Clin Rheumatol"},{"key":"BFncponc0688_CR47","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1046\/j.1365-2036.1999.00488.x","volume":"13","author":"DY Graham","year":"1999","unstructured":"Graham DY and Malaty HM (1999) Alendronate gastric ulcers. Aliment Pharmacol Ther 13: 515\u2013519","journal-title":"Aliment Pharmacol Ther"},{"key":"BFncponc0688_CR48","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/rheumatology\/34.5.479","volume":"34","author":"S De","year":"1995","unstructured":"De S et al. (1995) Pamidronate and uveitis. Br J Rheumatol 34: 479","journal-title":"Br J Rheumatol"},{"key":"BFncponc0688_CR49","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/sj.eye.6701461","volume":"19","author":"JM Durnian","year":"2005","unstructured":"Durnian JM et al. (2005) Bilateral acute uveitis and conjunctivitis after zoledronic therapy. Eye 19: 221\u2013222","journal-title":"Eye"},{"key":"BFncponc0688_CR50","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJM200303203481225","volume":"348","author":"FW Fraunfelder","year":"2003","unstructured":"Fraunfelder FW and Fraunfelder FT (2003) Bisphosphonates and ocular inflammation. N Engl J Med 348: 1187\u20131188","journal-title":"N Engl J Med"},{"key":"BFncponc0688_CR51","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0140-6736(83)91465-4","volume":"1","author":"HM Bounameaux","year":"1983","unstructured":"Bounameaux HM et al. (1983) Renal failure associated with intravenous diphosphonates. Lancet 1: 471","journal-title":"Lancet"},{"key":"BFncponc0688_CR52","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra022308","volume":"349","author":"JT Chang","year":"2003","unstructured":"Chang JT et al. (2003) Renal failure with the use of zoledronic acid. N Engl J Med 349: 1676\u20131679","journal-title":"N Engl J Med"},{"key":"BFncponc0688_CR53","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","volume":"12","author":"GS Markowitz","year":"2001","unstructured":"Markowitz GS et al. (2001) Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12: 1164\u20131172","journal-title":"J Am Soc Nephrol"},{"key":"BFncponc0688_CR54","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1345\/aph.1E589","volume":"39","author":"A Munier","year":"2005","unstructured":"Munier A et al. (2005) Zoledronic acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother 39: 1194\u20131197","journal-title":"Ann Pharmacother"},{"key":"BFncponc0688_CR55","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS et al. (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7: 377\u2013387","journal-title":"Cancer J"},{"key":"BFncponc0688_CR56","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","volume":"64","author":"GS Markowitz","year":"2003","unstructured":"Markowitz GS et al. (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64: 281\u2013289","journal-title":"Kidney Int"},{"key":"BFncponc0688_CR57","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","volume":"63","author":"R Marx","year":"2005","unstructured":"Marx R et al. (2005) Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaw: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63: 1567\u20131575","journal-title":"J Oral Maxillofac Surg"},{"key":"BFncponc0688_CR58","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S0278-2391(03)00328-8","volume":"61","author":"J Wang","year":"2003","unstructured":"Wang J et al. (2003) Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61: 1104\u20131107","journal-title":"J Oral Maxillofac Surg"},{"key":"BFncponc0688_CR59","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","volume":"62","author":"SL Ruggiero","year":"2004","unstructured":"Ruggiero SL et al. (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62: 527\u2013534","journal-title":"J Oral Maxillofac Surg"},{"key":"BFncponc0688_CR60","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.joms.2003.09.001","volume":"61","author":"P Tarassoff","year":"2003","unstructured":"Tarassoff P and Csermak K (2003) Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 61: 1238\u20131239","journal-title":"J Oral Maxillofac Surg"},{"key":"BFncponc0688_CR61","doi-asserted-by":"crossref","first-page":"413","DOI":"10.5694\/j.1326-5377.2005.tb06761.x","volume":"182","author":"G Carter","year":"2001","unstructured":"Carter G et al. (2001) Bisphosphonates and avascular necrosis of the jaw. Med J Aust 182: 413\u2013415","journal-title":"Med J Aust"},{"key":"BFncponc0688_CR62","doi-asserted-by":"publisher","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A et al. (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23: 8580\u20138587","journal-title":"J Clin Oncol"},{"key":"BFncponc0688_CR63","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1056\/NEJM200507073530120","volume":"353","author":"BG Durie","year":"2005","unstructured":"Durie BG et al. (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353: 99\u2013102","journal-title":"N Engl J Med"},{"key":"BFncponc0688_CR64","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jcms.2005.07.007","volume":"33","author":"JH Lenz","year":"2005","unstructured":"Lenz JH et al. (2005) Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? Craniomaxillofac Surg 33: 395\u2013403","journal-title":"Craniomaxillofac Surg"},{"key":"BFncponc0688_CR65","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1754-4505.2002.tb01178.x","volume":"22","author":"EC Sung","year":"2002","unstructured":"Sung EC et al. (2002) Osteonecrosis of the maxilla as a complication to chemotherapy: a case report. Spec Care Dentist 22: 142\u2013146","journal-title":"Spec Care Dentist"},{"key":"BFncponc0688_CR66","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/hed.2890040313","volume":"4","author":"HC Schwartz","year":"1982","unstructured":"Schwartz HC (1982) Osteonecrosis of the jaws: a complication of cancer chemotherapy. Head Neck Surg 4: 251\u2013253","journal-title":"Head Neck Surg"},{"key":"BFncponc0688_CR67","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1359\/jbmr.1999.14.7.1061","volume":"14","author":"S Manolagas","year":"1999","unstructured":"Manolagas S and Weinstein R (1999) New developments in the pathogenesis and treatment of steroid-induced osteoporosis J Bone Miner Res 14: 1061\u20131066","journal-title":"J Bone Miner Res"},{"key":"BFncponc0688_CR68","doi-asserted-by":"publisher","first-page":"138","DOI":"10.2106\/00004623-196042010-00011","volume":"42A","author":"HM Frost","year":"1960","unstructured":"Frost HM (1960) In vivo osteocyte death. J Bone Joint Surg 42A: 138\u2013143","journal-title":"J Bone Joint Surg"},{"key":"BFncponc0688_CR69","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/0278-2391(95)90130-2","volume":"53","author":"J Cowan","year":"1995","unstructured":"Cowan J et al. (1995) Glucocorticoid therapy for myasthenia gravis resulting in resorption of the mandibular condyles. J Oral Maxillofac Surg 53: 1091\u20131096","journal-title":"J Oral Maxillofac Surg"},{"key":"BFncponc0688_CR70","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1182\/blood-2005-08-3450","volume":"107","author":"G Anderson","year":"2006","unstructured":"Anderson G et al. (2006) Thalidomide derivative CC-4047 inhibits osteoclast formation by down regulation of PU.1. Blood 107: 3098\u20133105","journal-title":"Blood"},{"key":"BFncponc0688_CR71","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/07357900500283101","volume":"23","author":"E Crane","year":"2005","unstructured":"Crane E and List A (2005) Immunomodulatory drugs. Cancer Invest 23: 625\u2013634","journal-title":"Cancer Invest"},{"key":"BFncponc0688_CR72","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/j.1600-051X.2005.00842.x","volume":"32","author":"G Ficarra","year":"2005","unstructured":"Ficarra G et al. (2005) Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 32: 1123\u20131128","journal-title":"J Clin Periodontol"},{"key":"BFncponc0688_CR73","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S1079-2104(97)90314-0","volume":"83","author":"J Epstein","year":"1997","unstructured":"Epstein J et al. (1997) Postradiation osteonecrosis of the mandible: a long-term follow-up study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 83: 657\u2013662","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"BFncponc0688_CR74","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1200\/JCO.2003.99.132","volume":"21","author":"CA Migliorati","year":"2003","unstructured":"Migliorati CA (2003) Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21: 4253\u20134254","journal-title":"J Clin Oncol"},{"key":"BFncponc0688_CR75","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1503\/cmaj.050640","volume":"172","author":"E Wooltorton","year":"2005","unstructured":"Wooltorton E (2005) Patients receiving intravenous bisphosphonates should avoid invasive dental procedures. CMAJ 172: 1684","journal-title":"CMAJ"},{"key":"BFncponc0688_CR76","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.14219\/jada.archive.2005.0110","volume":"136","author":"MD Melo","year":"2005","unstructured":"Melo MD and Obeid G (2005) Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc 136: 1675\u20131681","journal-title":"J Am Dent Assoc"},{"key":"BFncponc0688_CR77","doi-asserted-by":"publisher","first-page":"7317","DOI":"10.1074\/jbc.M412817200","volume":"280","author":"LI Plotkin","year":"2005","unstructured":"Plotkin LI et al. (2005) Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 280: 7317\u20137325","journal-title":"J Biol Chem"},{"key":"BFncponc0688_CR78","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1359\/JBMR.040305","volume":"19","author":"PJ Bekker","year":"2004","unstructured":"Bekker PJ et al. (2004) A single dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to nuclear factor-B ligand (RANKL), in postmenopausal women. J Bone Miner Res 19: 1059\u20131066","journal-title":"J Bone Miner Res"},{"key":"BFncponc0688_CR79","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1210\/jc.2004-2126","volume":"90","author":"MG Murphy","year":"2005","unstructured":"Murphy MG et al. (2005) Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 90: 2022\u20132028","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncponc0688_CR80","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1124\/jpet.102.035295","volume":"302","author":"J Wood","year":"2002","unstructured":"Wood J et al. (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302: 1055\u20131061","journal-title":"J Pharmacol Exp Ther"},{"key":"BFncponc0688_CR81","first-page":"1080","volume":"8","author":"D Santini","year":"2002","unstructured":"Santini D et al. (2002) Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 8: 1080\u20131084","journal-title":"Clin Cancer Res"},{"key":"BFncponc0688_CR82","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/annonc\/mdg194","volume":"14","author":"B Vincenzi","year":"2003","unstructured":"Vincenzi B et al. (2003) Bisphosphonates: new antiangiogenic molecules in cancer treatment? Ann Oncol 14: 806\u2013807","journal-title":"Ann Oncol"},{"key":"BFncponc0688_CR83","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/3-540-31271-4","volume-title":"Bisphosphonat-Manual","author":"R Bartl","year":"2006","unstructured":"Bartl R et al. (2006) Bisphosphonate. [German] In Bisphosphonat-Manual, 83\u201388 (Eds Bartl R et al.) New York: Springer Berlin-Heidelberg"},{"key":"BFncponc0688_CR84","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10006-005-0670-0","volume":"10","author":"MH Abu-Id","year":"2006","unstructured":"Abu-Id MH et al. (2006) Bisphosphonate-associated osteonecrosis of the jaw [German]. Mund Kiefer Gesichtschir 10: 73\u201381","journal-title":"Mund Kiefer Gesichtschir"},{"key":"BFncponc0688_CR85","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","volume":"24","author":"A Badros","year":"2006","unstructured":"Badros A et al. (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24: 945\u2013952","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"BFncponc0688_CR86","first-page":"E88","volume":"10","author":"JV Bagan","year":"2005","unstructured":"Bagan JV et al. (2005) Avascular jaw osteonecrosis in association cancer chemotherapy: series of 10 cases. Med Oral Patol Oral Cir Bucal 10 (Suppl 2): E88\u2013E91","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"BFncponc0688_CR87","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.oraloncology.2005.08.001","volume":"42","author":"JV Bagan","year":"2005","unstructured":"Bagan JV et al. (2005) Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions\u2014study of 20 cases. Oral Oncol 42: 327\u2013329","journal-title":"Oral Oncol"},{"key":"BFncponc0688_CR88","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/01.mlg.0000187398.51857.3c","volume":"116","author":"MC Farrugia","year":"2006","unstructured":"Farrugia MC et al. (2006) Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 116: 115\u2013120","journal-title":"Laryngoscope"},{"key":"BFncponc0688_CR89","doi-asserted-by":"crossref","first-page":"549","DOI":"10.5694\/j.1326-5377.2005.tb07172.x","volume":"183","author":"SD Gibbs","year":"2005","unstructured":"Gibbs SD et al. (2005) Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention. Med J Aust 183: 549\u2013550","journal-title":"Med J Aust"},{"key":"BFncponc0688_CR90","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1634\/theoncologist.10-10-842","volume":"10","author":"V Guarneri","year":"2005","unstructured":"Guarneri V et al. (2005) Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 10: 842\u2013848","journal-title":"Oncologist"},{"key":"BFncponc0688_CR91","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10006-005-0624-6","volume":"9","author":"S Hoefert","year":"2005","unstructured":"Hoefert S and Eufinger H (2005) Kieferknochennekrosen als m\u00f6gliche unerw\u00fcnschte Wirkung von Bisphosphonaten [German]. Mund Kiefer Gesichts Chir 9: 233\u2013238","journal-title":"Mund Kiefer Gesichts Chir"},{"issue":"Suppl 1","key":"BFncponc0688_CR92","first-page":"S55","volume":"20","author":"A Hoff","year":"2005","unstructured":"Hoff A et al. (2005) Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy [abstract #1218]. J Bone Miner Res 20 (Suppl 1): S55","journal-title":"J Bone Miner Res"},{"key":"BFncponc0688_CR93","first-page":"2537","volume":"1","author":"AF Junod","year":"2005","unstructured":"Junod AF et al. (2005) Osteonecrosis of the jaws and bisphosphonates [French]. Rev Med Suisse 1: 2537\u20132540","journal-title":"Rev Med Suisse"},{"key":"BFncponc0688_CR94","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.amjmed.2004.04.015","volume":"117","author":"G Lugassy","year":"2004","unstructured":"Lugassy G et al. (2004) Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med 117: 440\u2013441","journal-title":"Am J Med"},{"key":"BFncponc0688_CR95","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1056\/NEJM200507073530120","volume":"353","author":"M Maerevoet","year":"2005","unstructured":"Maerevoet M et al. (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353: 99\u2013102","journal-title":"N Engl J Med"},{"key":"BFncponc0688_CR96","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.14219\/jada.archive.2005.0109","volume":"136","author":"MR Markiewicz","year":"2005","unstructured":"Markiewicz MR et al. (2005) Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. J Am Dent Assoc 136: 1669\u20131674","journal-title":"J Am Dent Assoc"},{"key":"BFncponc0688_CR97","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61: 1115\u20131118","journal-title":"J Oral Maxillofac Surg"},{"key":"BFncponc0688_CR98","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/j.1600-0714.2005.00351.x","volume":"34","author":"E Merigo","year":"2005","unstructured":"Merigo E et al. (2005) Jawbone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. J Oral Pathol Med 34: 613\u2013617","journal-title":"J Oral Pathol Med"},{"key":"BFncponc0688_CR99","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/S0755-4982(05)84119-3","volume":"34","author":"SA Najm","year":"2005","unstructured":"Najm SA et al. (2005) Bisphosphonates-related jaw osteonecrosis [French]. Presse Med 34: 1073\u20131077","journal-title":"Presse Med"},{"key":"BFncponc0688_CR100","first-page":"E76","volume":"11","author":"D Pastor-Zuazaga","year":"2006","unstructured":"Pastor-Zuazaga D et al. (2006) Osteonecrosis of the jaws and bisphosphonates: report of three cases. Med Oral Patol Oral Cir Bucal 11: E76\u2013E79","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"BFncponc0688_CR101","doi-asserted-by":"crossref","first-page":"417","DOI":"10.5694\/j.1326-5377.2005.tb06762.x","volume":"182","author":"PM Purcell","year":"2005","unstructured":"Purcell PM and Boyd IW (2005) Bisphosphonates and osteonecrosis of the jaw. Med J Aust 182: 417\u2013418","journal-title":"Med J Aust"},{"key":"BFncponc0688_CR102","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1093\/annonc\/mdi206","volume":"16","author":"G Sanna","year":"2005","unstructured":"Sanna G et al. (2005) Jaw avascular bone necrosis associated with long-term use of bisphosphonates. Ann Oncol 16: 1207\u20131208","journal-title":"Ann Oncol"},{"key":"BFncponc0688_CR103","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s10006-005-0616-6","volume":"9","author":"I Schirmer","year":"2005","unstructured":"Schirmer I et al. (2005) Bisphosphonates and osteonecrosis of the jaw [German]. Mund Kiefer Gesichtschir 9: 239\u2013245","journal-title":"Mund Kiefer Gesichtschir"},{"key":"BFncponc0688_CR104","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.joms.2004.03.005","volume":"62","author":"HC Schwartz","year":"2004","unstructured":"Schwartz HC (2004) Osteonecrosis and bisphosphonates: correlation versus causation. J Oral Maxillofac Surg 62: 763\u2013764","journal-title":"J Oral Maxillofac Surg"},{"key":"BFncponc0688_CR105","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ajh.20481","volume":"81","author":"R Zarychanski","year":"2006","unstructured":"Zarychanski R et al. (2006) Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol 81: 73\u201375","journal-title":"Am J Hematol"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncponc0688.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0688","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ncponc0688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0688.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:44:51Z","timestamp":1684442691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc0688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":105,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["BFncponc0688"],"URL":"https:\/\/doi.org\/10.1038\/ncponc0688","relation":{},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}